CN103582490B - 作为治疗剂的肝细胞生长因子模拟物 - Google Patents

作为治疗剂的肝细胞生长因子模拟物 Download PDF

Info

Publication number
CN103582490B
CN103582490B CN201280026925.2A CN201280026925A CN103582490B CN 103582490 B CN103582490 B CN 103582490B CN 201280026925 A CN201280026925 A CN 201280026925A CN 103582490 B CN103582490 B CN 103582490B
Authority
CN
China
Prior art keywords
hgf
growth factor
hepatocyte growth
met
dihexa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280026925.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103582490A (zh
Inventor
J·W·哈丁
J·W·赖特
C·C·伯努瓦
L·H·卡瓦斯
G·A·韦曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington State University WSU
Original Assignee
Washington State University WSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington State University WSU filed Critical Washington State University WSU
Publication of CN103582490A publication Critical patent/CN103582490A/zh
Application granted granted Critical
Publication of CN103582490B publication Critical patent/CN103582490B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
CN201280026925.2A 2011-04-02 2012-04-02 作为治疗剂的肝细胞生长因子模拟物 Active CN103582490B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161471122P 2011-04-02 2011-04-02
US201161471124P 2011-04-02 2011-04-02
US61/471,124 2011-04-02
US61/471,122 2011-04-02
PCT/US2012/031815 WO2012138599A2 (en) 2011-04-02 2012-04-02 Hepatocyte growth factor mimics as therapeutic agents

Publications (2)

Publication Number Publication Date
CN103582490A CN103582490A (zh) 2014-02-12
CN103582490B true CN103582490B (zh) 2015-09-30

Family

ID=46969763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280026925.2A Active CN103582490B (zh) 2011-04-02 2012-04-02 作为治疗剂的肝细胞生长因子模拟物

Country Status (8)

Country Link
US (3) US9150613B2 (https=)
EP (1) EP2709650B1 (https=)
JP (1) JP6173298B2 (https=)
CN (1) CN103582490B (https=)
AU (1) AU2012240424B2 (https=)
CA (1) CA2832113C (https=)
ES (1) ES2622385T3 (https=)
WO (1) WO2012138599A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014052766A1 (en) * 2012-09-27 2014-04-03 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN104788537B (zh) * 2015-03-31 2018-03-13 中国科学院长春应用化学研究所 一种四肽化合物及其制备方法和应用
US11021514B2 (en) * 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN110716925B (zh) * 2019-09-05 2023-08-04 中电科大数据研究院有限公司 一种基于轨迹分析的跨境行为识别方法
US20230000943A1 (en) * 2021-06-29 2023-01-05 Synaptogenix, Inc. Method of inducing synaptogenesis by administering angiotensin and analogues thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805203A1 (en) * 1992-09-18 1997-11-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES The use of a substance which prevents HGS/SF from binding with Met
US20050113369A1 (en) * 2002-12-21 2005-05-26 Zembower David E. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019400A2 (en) * 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854388A (en) * 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805203A1 (en) * 1992-09-18 1997-11-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES The use of a substance which prevents HGS/SF from binding with Met
US20050113369A1 (en) * 2002-12-21 2005-05-26 Zembower David E. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2011019400A2 (en) * 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Angiotensin IV Analog Nle-Tyr-Leu-ψ-(CH2-NH2)3-4-His-Pro-Phe (Norleual) Can Act as a Hepatocyte Growth Factor/c-Met Inhibitor;B.J Yamamoto等;《The journal of pharmacology and experimental therapeutics》;20100430;第333卷(第1期);摘要、讨论部分 *

Also Published As

Publication number Publication date
US8598118B2 (en) 2013-12-03
AU2012240424B2 (en) 2017-10-26
WO2012138599A2 (en) 2012-10-11
EP2709650A2 (en) 2014-03-26
JP2014511858A (ja) 2014-05-19
US9150613B2 (en) 2015-10-06
NZ616210A (en) 2015-07-31
US20140088004A1 (en) 2014-03-27
EP2709650B1 (en) 2017-02-08
ES2622385T3 (es) 2017-07-06
WO2012138599A3 (en) 2013-01-17
JP6173298B2 (ja) 2017-08-02
CA2832113A1 (en) 2012-10-11
HK1196075A1 (en) 2014-12-05
EP2709650A4 (en) 2015-04-22
US20130165392A1 (en) 2013-06-27
US20170049843A1 (en) 2017-02-23
CN103582490A (zh) 2014-02-12
CA2832113C (en) 2020-07-21
AU2012240424A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
CN103582490B (zh) 作为治疗剂的肝细胞生长因子模拟物
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
US20140094413A1 (en) Hepatocyte growth factor (hgf) mimics as therapeutic agents
KR20120082909A (ko) 합성 마이오스타틴 펩티드 길항제
US9051351B2 (en) Hepatocyte growth factor mimics as therapeutic agents
CN114846020A (zh) 逆向-反转肽
US11083773B2 (en) Peptides that block leukocyte recruitment and methods of use
KR102532557B1 (ko) Dsg2 유래 펩타이드
JP2003502295A (ja) 脳由来神経栄養因子の小さな環状模擬体
NZ616210B2 (en) Hepatocyte growth factor mimics as therapeutic agents
HK1196075B (en) Hepatocyte growth factor mimics as therapeutic agents
Class et al. Patent application title: HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS Inventors: Joseph W. Harding (Pullman, WA, US) John W. Wright (Pullman, WA, US) Caroline C. Benoist (Nashville, TN, US) Leen H. Kawas (Pullman, WA, US) Gary A. Wayman (Pullman, WA, US) Assignees: WASHINGTON STATE UNIVERSITY
WO2019234157A1 (en) Amyloid inhibitory peptides
Kawas Development of therapeutics targeting the hepatocyte growth factor (HGF)/MET system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: UNIV WASHINGTON STATE

Free format text: FORMER OWNER: WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION

Effective date: 20141127

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141127

Address after: Washington State

Applicant after: Washington State University

Address before: Washington, USA

Applicant before: Washington State University Research Foundation

C14 Grant of patent or utility model
GR01 Patent grant